97 related articles for article (PubMed ID: 22971530)
1. The effect of the combination of bisphosphonates and conventional chemotherapy on bone metabolic markers in multiple myeloma patients.
Zhang X; Chang C; Zhao Y; Wu L; Zhang Z; Li X
Hematology; 2012 Sep; 17(5):255-60. PubMed ID: 22971530
[TBL] [Abstract][Full Text] [Related]
2. [The affection of bisphosphonates combined with chemotherapy on bone metabolism index in multiple myeloma].
Zhang X; Chang CK; Wu LY; Zhang Z; Zhou LY; Xiao C; Li X
Zhonghua Xue Ye Xue Za Zhi; 2011 Oct; 32(10):660-3. PubMed ID: 22339822
[TBL] [Abstract][Full Text] [Related]
3. [Efficacy of zoledronic acid combined with chemotherapy in treatment of skeletal metastases of non-small cell lung cancer and the bone metabolic markers].
Hu XY; Zou QF; Jin C; Li WD; Chen WS; Ma L
Nan Fang Yi Ke Da Xue Xue Bao; 2010 Jun; 30(6):1343-6. PubMed ID: 20584674
[TBL] [Abstract][Full Text] [Related]
4. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates.
Fizazi K; Lipton A; Mariette X; Body JJ; Rahim Y; Gralow JR; Gao G; Wu L; Sohn W; Jun S
J Clin Oncol; 2009 Apr; 27(10):1564-71. PubMed ID: 19237632
[TBL] [Abstract][Full Text] [Related]
5. Everolimus and zoledronic acid in patients with renal cell carcinoma with bone metastases: a randomized first-line phase II trial.
Broom RJ; Hinder V; Sharples K; Proctor J; Duffey S; Pollard S; Fong PC; Forgeson G; Harris DL; Jameson MB; O'Donnell A; North RT; Deva S; Hanning FJ; Grey A; Findlay MP
Clin Genitourin Cancer; 2015 Feb; 13(1):50-8. PubMed ID: 25163397
[TBL] [Abstract][Full Text] [Related]
6. [Relationship of osteolytic biochemical indicators of bone metabolism with the therapeutic effect in breast cancer patients with bone metastases].
Li SF; Wang XR; Wang C; Chen Y; Ren L; Cui L; Tong ZS
Zhonghua Zhong Liu Za Zhi; 2009 Dec; 31(12):911-5. PubMed ID: 20193330
[TBL] [Abstract][Full Text] [Related]
7. Serum N-telopeptide and bone-specific alkaline phosphatase levels in patients with osteonecrosis of the jaw receiving bisphosphonates for bone metastases.
Morris PG; Fazio M; Farooki A; Estilo C; Mallam D; Conlin A; Patil S; Fleisher M; Cremers S; Huryn J; Hudis CA; Fornier MN
J Oral Maxillofac Surg; 2012 Dec; 70(12):2768-75. PubMed ID: 22330331
[TBL] [Abstract][Full Text] [Related]
8. Bone Marker-Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Results of the Z-MARK Study.
Raje N; Vescio R; Montgomery CW; Badros A; Munshi N; Orlowski R; Hadala JT; Warsi G; Argonza-Aviles E; Ericson SG; Anderson KC
Clin Cancer Res; 2016 Mar; 22(6):1378-84. PubMed ID: 26644410
[TBL] [Abstract][Full Text] [Related]
9. Prospective study of urinary and serum cross-linked N-telopeptide of type I collagen (NTx) for diagnosis of bone metastasis in patients with lung cancer.
Tamiya M; Tokunaga S; Okada H; Suzuki H; Kobayashi M; Sasada S; Okamoto N; Morishita N; Matsuura Y; Miyamoto N; Hattori M; Taira K; Daga H; Takeda K; Hirashima T
Clin Lung Cancer; 2013 Jul; 14(4):364-9. PubMed ID: 23276824
[TBL] [Abstract][Full Text] [Related]
10. First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma.
Tosi P; Zamagni E; Cellini C; Parente R; Cangini D; Tacchetti P; Perrone G; Ceccolini M; Boni P; Tura S; Baccarani M; Cavo M
Eur J Haematol; 2006 May; 76(5):399-404. PubMed ID: 16480429
[TBL] [Abstract][Full Text] [Related]
11. Additive effect of zoledronic acid on serum prostate-specific antigen changes for hormone-sensitive prostate cancer patients with bone metastasis treated by combined androgen blockade.
Kamiya N; Suzuki H; Endo T; Takano M; Yano M; Naoi M; Nishimi D; Kawamura K; Imamoto T; Ichikawa T
Int J Urol; 2012 Feb; 19(2):169-73. PubMed ID: 22126137
[TBL] [Abstract][Full Text] [Related]
12. Serial markers of bone turnover in men with metastatic prostate cancer treated with zoledronic Acid for detection of bone metastases progression.
Lein M; Wirth M; Miller K; Eickenberg HU; Weissbach L; Schmidt K; Haus U; Stephan C; Meissner S; Loening SA; Jung K
Eur Urol; 2007 Nov; 52(5):1381-7. PubMed ID: 17321667
[TBL] [Abstract][Full Text] [Related]
13. [The relationships between biomarkers of age-related changes in bone turnover and bone mineral density in healthy Chinese women].
Liu H; Liao EY; Wu XP; Zhang H; Luo XH; Xie H; Cao XZ; Liu SP
Zhonghua Nei Ke Za Zhi; 2004 Nov; 43(11):805-9. PubMed ID: 15634535
[TBL] [Abstract][Full Text] [Related]
14. Bone metabolism markers: Indicators of loading dose intravenous ibandronate treatment for bone metastases from breast cancer.
Wang R; Zhang S; Jiang Z; Tian J; Wang T; Song S
Clin Exp Pharmacol Physiol; 2017 Jan; 44(1):88-93. PubMed ID: 27716993
[TBL] [Abstract][Full Text] [Related]
15. [Age-related change of bone biochemical markers and their relationships to mineral density in healthy Chinese men].
Zhao Q; Shen LX; Zhang H; Wu XP; Xie H; Shan PF; Cao XZ; Liao EY; Luo XH
Zhonghua Yi Xue Za Zhi; 2006 Jul; 86(28):1957-61. PubMed ID: 17064589
[TBL] [Abstract][Full Text] [Related]
16. Clinical value of bone remodelling markers in patients with bone metastases treated with zoledronic acid.
Pectasides D; Nikolaou M; Farmakis D; Kanakis I; Gaglia A; Kountourakis P; Karamanos NK; Economopoulos T; Raptis SA
Anticancer Res; 2005; 25(2B):1457-63. PubMed ID: 15865105
[TBL] [Abstract][Full Text] [Related]
17. [Effects of Migu tablet on bone mineral density, serum matrix metalloproteinase-2 level and bone metabolic markers in postmenopausal osteoporosis].
Dai Y; Shen L
Zhongguo Zhong Yao Za Zhi; 2007 Nov; 32(22):2409-12. PubMed ID: 18257271
[TBL] [Abstract][Full Text] [Related]
18. Serum N-telopeptide of type I collagen and bone alkaline phosphatase and their relationship in patients with non-small cell lung carcinoma and bone metastases. Preliminary results.
Lumachi F; Marino F; Fanti G; Chiara GB; Basso SM
Anticancer Res; 2011 Nov; 31(11):3879-81. PubMed ID: 22110213
[TBL] [Abstract][Full Text] [Related]
19. Effect of pamidronate administration on markers of bone turnover and disease activity in multiple myeloma.
Terpos E; Palermos J; Tsionos K; Anargyrou K; Viniou N; Papassavas P; Meletis J; Yataganas X
Eur J Haematol; 2000 Nov; 65(5):331-6. PubMed ID: 11092464
[TBL] [Abstract][Full Text] [Related]
20. Serologic bone markers for predicting development of osteonecrosis of the jaw in patients receiving bisphosphonates.
Lazarovici TS; Mesilaty-Gross S; Vered I; Pariente C; Kanety H; Givol N; Yahalom R; Taicher S; Yarom N
J Oral Maxillofac Surg; 2010 Sep; 68(9):2241-7. PubMed ID: 20728033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
